Tackling Cancer with a New Paradigm

Dr. Lieping Chen, a founding member of the ACGT Scientific Advisory Council, is one of the very early pioneers in the field of pd-1 inhibitors, which has now led to the September, 2014 FDA approval of Keytruda for treating advanced melanoma. In the December Medicine@Yale article “Tackling cancer with a new paradigm,” Chen discusses how the new class of drugs, which uses antibodies to guide the immune system in fighting tumors, shows promise for many cancers including bladder, kidney and lung cancers.  Read more about the exciting progress.